Tezspire Dosing for Severe Asthma
Tezspire (tezepelumab-ekko) is dosed at 210 mg subcutaneously every 4 weeks in adult patients with severe asthma, regardless of biomarker levels or inflammatory phenotype.
Standard Dosing Regimen
The FDA-approved dosing is straightforward and universal:
- Dose: 210 mg subcutaneous injection
- Frequency: Every 4 weeks (monthly)
- Route: Subcutaneous injection in abdomen, thigh, or upper arm
- No dose adjustments needed for renal or hepatic impairment
- No biomarker requirements for initiation 1
Administration Technique
Patient or caregiver should be trained to:
- Prepare the medication properly
- Wash hands thoroughly and clean injection site with alcohol wipe
- Inject subcutaneously using auto-injector or pre-filled syringe
- Rotate injection sites (abdomen, thigh, or upper arm) 1
Clinical Context and Patient Selection
Tezepelumab is unique among asthma biologics as it targets thymic stromal lymphopoietin (TSLP), an upstream epithelial alarmin that drives both type 2 and non-type 2 inflammation. This mechanism allows for broad applicability across asthma phenotypes 1, 2.
When to Choose Tezepelumab:
- Type 2 asthma: Effective option alongside dupilumab 1
- Non-type 2 asthma: Only biologic with proven efficacy in this population 1
- Mixed or unclear phenotype: Excellent choice when inflammatory profile is uncertain
- Patients with persistent airflow obstruction: Demonstrated efficacy in improving lung function 3
- Prior biologic failure: Real-world data shows effectiveness in biologic-experienced patients 4
Expected Clinical Outcomes
Based on recent high-quality evidence, patients typically experience:
Exacerbation Reduction:
- 74-76% reduction in annualized asthma exacerbation rates in real-world studies 5, 6
- Consistent benefit across both high and low eosinophil counts (60% reduction even in patients with <300 cells/μL) 5
Lung Function Improvement:
- Mean FEV1 improvement of 0.11-0.24 L by 6 months 7, 5, 6
- Greater improvements in patients with baseline FEV1 ≤80% predicted (0.19 L) 6
- Benefits in both large and small airway function 7
Symptom Control:
- Clinically meaningful improvements in ACT, ACQ-6, and quality of life scores within 3-6 months 7, 8, 6
- Significant reduction in oral corticosteroid requirements, with many patients achieving complete OCS withdrawal 7, 4
Important Clinical Considerations
Onset of Action: Clinical improvements typically become apparent within 1-3 months, with continued benefit through 6-12 months 7, 8
Phenotype-Specific Response: While effective across all phenotypes, T2-high patients show higher rates of "complete response" (52% vs 17% in non-T2), though non-T2 patients still achieve predominantly "good response" 4. The magnitude of benefit is somewhat smaller in T2-low patients, but tezepelumab remains the only biologic option for this population 2.
Safety Profile: Excellent safety demonstrated across diverse populations including:
- Black/African American patients
- Adolescents
- Patients with comorbid mild-moderate COPD
- Smokers (≥10 pack-years)
- No serious adverse events reported in recent real-world studies 7, 8, 6
Common Pitfalls to Avoid
- Don't delay initiation waiting for specific biomarker thresholds—tezepelumab works regardless of eosinophil count or IgE levels
- Don't discontinue prematurely—allow at least 3-6 months to assess full therapeutic response
- Don't overlook non-T2 patients—this is the only biologic proven effective in this historically difficult-to-treat population
- Don't forget comorbidity assessment—evaluate for chronic rhinosinusitis, nasal polyps, eosinophilic conditions, and atopic dermatitis, as these may also improve 1